intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

BOSTON -- In adults hospitalized for acute infections, cefepime and piperacillin-tazobactam turned out to be equally safe in terms of serious kidney outcomes, although the latter antibiotic showed a ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

Two 'big gun' antibiotics thought to cause kidney failure in ICU patients with a severe bacterial infection, especially when combined with another antibiotic, may be safer for the kidneys than ...

People believed to have sepsis who take piperacillin-tazobactam (Zosyn) and vancomycin have a 5% absolute mortality increase at 90 days compared with those who take cefepime and vancomycin, a new ...

Cefepime-taniborbactam was 22% more effective than meropenem, which is a current treatment for complicated urinary tract infections (UTIs) and acute pyelonephritis, according to a study published in ...

The FDA approved the combination of cefepime and enmetazobactam (Exblifep) for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by designated ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

The coadministration of piperacillin-tazobactam and vancomycin may raise the risk for AKI, according to a warning from the US Food and Drug Administration. The ACORN trial included 2511 adults ...